- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05071781
Effect of CRH on Duodenal Markers and Gastric Sensorimotor Function
The Effect of Corticotropin Release Hormone on Duodenal Markers and Gastric Sensorimotor Function in Healthy Volunteers
In the present study, during Part 1, after a baseline gastroduodenoscopy, the investigators will perform a gastroduodenoscopy twice, to take duodenal biopsies before and 2 hours after administration of CRH/placebo. The investigators will measure mucosal integrity and markers of immune activation as outlined in Parts A and B, and will use transmission electron microscopy to evaluate mast cell and eosinophil degranulation. After an interval period of at least 1 week, CRH or placebo will be administrated again in a crossover fashion.
As a complementary study, the investigators will also test the effect of ex vivo mast cell blockade by lodoxamide to evaluate whether mast cells are involved in the hypothesized effect of CRH on duodenal permeability.
In a second part of this study, Part 2, the investigators will perform a gastric barostat, to measure the gastric accommodation and sensitivity to distension, and a carbon-13-octanoic acid breath test to measure the gastric emptying time after administration of CRH/placebo.
Healthy volunteers will have the option to choose to which part of the study (part 1 or 2) they wish to participate. They can also choose to cooperate to both study parts if preferred.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Leuven, Belgia, 3000
- Rekruttering
- I-Hsuan Huang
-
Ta kontakt med:
- I-Hsuan Huang
- Telefonnummer: 016194938
- E-post: ihsuan.huang@kuleuven.be
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Voluntary written informed consent of the participant has been obtained prior to any screening procedures
- Women of child-bearing potential agree to apply a highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses.
- Healthy volunteers
- Subjects aged 18-55 years old (55y included).
- Male or female subjects.
- Subjects who are capable to understand the study and the questionnaires, and to comply with the study requirements.
Exclusion Criteria:
- Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol
- Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
- Presence of a history of gastrointestinal surgery other than appendectomy
- Presence of organic or functional gastrointestinal disease
- Presence of gastro-intestinal symptoms
- Major psychiatric disorder such as major depression
- Presence of any disease affecting the gastrointestinal tract or hepatobiliary system.
- History of allergic reaction to CRH
- BMI equal to 30 mg/kg² or higher.
Use of drugs included in this list:
- Opioids (unless short intake for acute pain and > 1month ago)
- Amitriptyline or mirtazapine; other antidepressants are allowed if the HV is on a stable dose and the drug is not combined with other antidepressants.
- Corticosteroids
- Antihistaminic drugs (last 2 weeks)
- Proton pump inhibitors (last 2 weeks)
- Disodiumchromoglycate or other mast cell stabilizers (last 2 weeks)
- Leukotriene receptor antagonists (last 2 weeks)
- NSAIDs (last 2 weeks)
- Antibiotics (last 2 months)
- Probiotics (last 2 weeks)
- Other medication: to be discussed with physician
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Cortisol releasing hormone group
HVs will start with CRH infusion.
|
intravenous CRH (100 µg)
a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
|
Placebo komparator: Placebo (sodium choride) group
HVs will start with NaCl 0.9% (placebo) infusion
|
intravenous CRH (100 µg)
a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The effect of corticotrophin release hormone (CRH) on duodenal mast cell count
Tidsramme: 2 hours after CRH/placebo
|
Duodenal mast cells (c-kit) will be counted per mm2 via stained duodenal biopsy sections.
|
2 hours after CRH/placebo
|
The effect of CRH on sensitivity to gastric distention (part 2)
Tidsramme: 30 minutes after CRH/placebo
|
Visceral sensitivity will be measured by barostat.
Discomfort threshold will be defined as the first level of pressure and the corresponding volume that provokes discomfort.
Pressure thresholds will be expressed both as pressures relative to minimal distending pressure and as absolute pressures.
|
30 minutes after CRH/placebo
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The effect of CRH on duodenal eosinophilia
Tidsramme: 2 hours after CRH/placebo
|
Duodenal eosinophils (H&E) will be counted per mm2 via stained duodenal biopsy sections.
|
2 hours after CRH/placebo
|
The effect of CRH on duodenal mucosal permeability
Tidsramme: 2 hours after CRH/placebo
|
Duodenal mucosa permeability on duodenal biopsies using adapted mini-Ussing chambers
|
2 hours after CRH/placebo
|
The effect of CRH on gastric emptying time
Tidsramme: 30 minutes after CRH/placebo
|
Gastric emptying time in minutes t (1/2) will be measured by 13C-octanoic acid breath test.
|
30 minutes after CRH/placebo
|
The effect of CRH on gastric accommodation
Tidsramme: 30 minutes after CRH/placebo
|
Gastric accommodation will be measured by barostat.
Accommodation to a meal will be expressed as the average increase in intragastric volume during the first 4 postprandial hours.
|
30 minutes after CRH/placebo
|
The effect of CRH on gastroduodenal symptoms.
Tidsramme: Every 15 minutes during CRH/placebo infusion for 4 hours
|
Assessments using Visual Analog Score for GI symptoms which including pain, nausea, bloating, vomiting.
|
Every 15 minutes during CRH/placebo infusion for 4 hours
|
The effect of CRH on salivary cortisol level
Tidsramme: Right before CRH/placebo injection, 15, 30, 60, 120 minutes after injection
|
Salivary cortisol level in nmol/L during placebo or CRH infusion
|
Right before CRH/placebo injection, 15, 30, 60, 120 minutes after injection
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- S65020
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på GI Motility Disorder
-
Ethicon Endo-SurgeryFullførtØvre GI; Lavere GI; GynekologiskStorbritannia, Forente stater, Italia
-
University of FloridaSchwabe North AmericaFullførtOverlevelse av probiotika under GI-transit | GI-symptomerForente stater
-
University of North Carolina, Chapel HillNovartis PharmaceuticalsFullført
-
McGill University Health Centre/Research Institute...Unity Health Toronto; Jewish General HospitalRekruttering
-
Nextrast, Inc.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Fullført
-
Duke UniversityTilbaketrukket
-
B. Braun Melsungen AGB.Braun Taiwan Co., Ltd.Fullført
-
University of PennsylvaniaFullførtThoraxkreft | GI-kreftForente stater
-
Oregon Health and Science UniversityAvsluttetGI-kolonisering av Vancomycin-resistente EnterococcusForente stater
-
University of ArkansasTilbaketrukketSolide masselesjoner i GI-kanalen
Kliniske studier på Corticotropin-release hormone
-
The Cleveland ClinicMallinckrodtFullførtPanuveitt | Fremre uveitt | Okulær sarkoidoseForente stater
-
Wake Forest University Health SciencesTilbaketrukket
-
Neuro-Ophthalmologic Associates, PCMallinckrodtFullførtOptisk nevrittForente stater
-
Eunice Kennedy Shriver National Institute of Child...FullførtSunn | Cushings syndrom | Hyperfunksjon av binyrene | BinyrehypofunksjonForente stater
-
Iraj Sabahi Research Inc.MallinckrodtUkjent
-
Providence Health & ServicesMallinckrodtFullførtMultippel sklerose, tilbakefallende-remitterendeForente stater
-
The Cleveland ClinicMallinckrodtTilbaketrukket
-
Dent Neuroscience Research CenterFullførtKronisk migreneForente stater
-
Mallinckrodt ARD LLCAvsluttetMultippel sklerose, tilbakefallende-remitterendeForente stater
-
University of Illinois at ChicagoMallinckrodtAvsluttetProteinuri | Transplantasjon av glomerulopatiForente stater